Dentsply Sirona (XRAY) reported its 1Q17 earnings on May 9, 2017. The company was created in February 2016 through the merging of companies Dentsply and Sirona.
Dentsply Sirona’s (XRAY) 1Q17 earnings and revenue failed to meet analysts’ estimates. The company reported a fall in its organic revenue.
On May 10, 2017, Allergan (AGN) was trading at a forward PE multiple of ~14.1x, as compared to the industry average of 11.9x.
In 1Q17, total revenues from Allergan’s International segment reached $737.3 million, as compared to $673.3 million in 1Q16.
In 1Q17, revenues from Allergan’s US General Medicine segment fell 7.4% to $1.35 billion, as compared to $1.45 billion in 1Q16.
In 1Q17, Allergan’s US Specialized Therapeutics segment revenues rose 14.1% to $1.48 billion, as compared to $1.30 billion in 1Q16.
Allergan (AGN) released its 1Q17 earnings on May 9, 2017, reporting a growth of 5.1% and revenues of ~$3.6 billion, as compared to $3.4 billion in 1Q16.
Alexion Pharmaceuticals has planned five clinical trials in 2017 to test the potential of investigational next-generation C5 antibody, ALXN1210, as a treatment option for complement-mediated diseases.
During its 1Q17 earnings conference call, Alexion Pharmaceuticals (ALXN) reiterated that its drug Soliris’s 2017 revenue would fall in the range of $3.0 billion–$3.1 billion.
While Soliris is expected to continue to be a key revenue driver for Alexion Pharmaceuticals (ALXN) in 2017, the company anticipates an increasingly negative impact on Solaris’s 2017 sales.
Alexion Pharmaceuticals (ALXN) expects to report revenue in the range of $3.4 billion–$3.5 billion in 2017.
Alexion Pharmaceuticals (ALXN) is focused on increasing its market share and defending its leading position in the complement inhibitor market in 2017.
Allergan’s stock price rose nearly 16.4% in the last 12 months. Estimates show that the stock has the potential to return ~11.7% over the next 12 months.
Allergan (AGN) is set to release its 1Q17 earnings on May 9, 2017. Analysts’ estimates show EPS at $3.30 on revenues of $3.53 billion for 1Q17.
Analysts estimate Allergan’s (AGN) revenues at $3.53 billion for 1Q17—a 6.9% fall compared to 1Q17. Various factors will impact growth during 1Q17.
Boston Scientific (BSX) was trading at $26.35 on May 4, 2017, as compared to its 50-day moving average of $24.93 and its 200-day moving average of $23.38.
Boston Scientific expects its 2017 operational revenues to witness a YoY rise of 6%–7%, as compared to the previous guidance range of 5%–7%.
In 1Q17, BSX MedSurg segment registered the highest growth out of the three business segments, reporting a YoY growth of ~15% on an operational basis.
On March 30, 2017, Boston Scientific (BSX) announced a definitive agreement to acquire Symetis for $435 million in cash.
Boston Scientific registered adjusted EPS (earnings per share) of $0.29 in 1Q17, which represents ~3.6% YoY (year-over-year) growth.